GT Biopharma Board Restructures with New Appointments: Hilary Kramer and Andrew Ritter Join, Bruce Wendel and Rajesh Shrotriya Resign

GT Biopharma's board of directors has been restructured with new appointments, including Hilary Kramer and Andrew Ritter as non-employee directors. The company's overall stock score is a "Underperform" according to Spark's AI Analyst, reflecting financial challenges such as lack of revenue, continuous losses, negative equity, and reliance on external financing.

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company, has announced significant changes to its board of directors. Hilary Kramer and Andrew Ritter have been appointed as non-employee directors, replacing Bruce Wendel and another outgoing member [1].

Hilary Kramer, the Founder and Chief Investment Officer of GreenTech Research, brings a wealth of experience in sustainable fund management and strategic operations. She has served on multiple boards, including RSL Communications Ltd., Deltathree Inc., and El Sitio Inc. Previously, she was Senior Managing Director and Chief Investment Officer for a $12 billion family office portfolio [1].

Andrew Ritter's appointment was not detailed in the provided materials.

The company's stock score is currently "Underperform" according to Spark's AI Analyst, reflecting financial challenges such as lack of revenue, continuous losses, negative equity, and reliance on external financing [1].

Despite these challenges, GT Biopharma remains focused on its TriKE® NK cell engager platform, which aims to harness and enhance the cancer-killing abilities of natural killer cells. The company holds an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology [1].

For more information, please visit GT Biopharma's website at gtbiopharma.com.

References:
[1] https://quantisnow.com/insight/gt-biopharma-appoints-new-member-to-its-board-of-directors-6037471